RxDoctor Payments Data

Steven Come, MD

Medical Oncology · Boston, MANPI 1619940137

Payments from drug & device makers

$420,958in general payments, 2019–2025

Across 22 payments — averaging $19,134 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$363K
  • AstraZeneca$58K

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.21$362,786
AstraZeneca1$58,172

How this compares

$420,958 in reported general payments places this provider in the 65th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$25,751
Medicare patients
141
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Exemestane11$2,338
Anastrozole44$958
Letrozole37$850
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$730
Lorazepam17$52

Paid to pharmacies, not to this prescriber.

Other medical oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →